Piper Jaffray’s Gitkin Sees Upticks in M&A/IPOs

Andrew Gitkin, head of West Coast biotechnology investment banking – Piper Jaffray, says ophthalmology start-ups stand to benefit from a “renaissance of information” that’s giving us a stronger understanding of patient needs. He looks ahead at the potential for more M&A by strategics and an open IPO market.